NCT01380678

Intralesional Bevacizumab Injection on Primary Pterygium

A Randomized Controlled Trial of Intralesional Bevacizumab Injection on Primary Pterygium: Preliminary Results

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 206 (estimated)
• Sponsor: Khon Kaen University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate that intralesional injection of bevacizumab on primary pterygium can reduce the corneal pterygium area, inflammation, redness and other symptoms.

Detailed description

To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment

Conditions

• Pterygium
• Inflammation

Interventions

Type	Name	Description
DRUG	Intralesional injection of bevacizumab	single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
DRUG	Topical antihistamine and vasoconstrictor	combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%

Timeline

• Start date: 2009-01-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2011-06-27
• Last updated: 2011-07-11

Locations

1 site across 1 country: Thailand